Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-06-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司第八届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and the matters approved, including amendments to the company charter and meeting rules, which are to be submitted to the shareholders' meeting. The document is an announcement of board decisions and changes related to governance documents, not the actual governance report or full board meeting minutes. It is not a full annual report, audit report, or financial report. The content fits best under Board/Management Information (MANG) as it announces board meeting resolutions and governance-related decisions.
2022-06-07 Chinese
金陵药业股份有限公司董事会议事规则（2022.06）
Governance Information Classification · 100% confidence The document is titled '金陵药业股份有限公司董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors of Jinling Pharmaceutical Co., Ltd.' It details the internal rules, procedures, powers, and responsibilities of the company's board of directors, including meeting protocols, decision-making processes, and governance structure. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance practices and board management. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and it is not an announcement or a brief notice, but a detailed governance document.
2022-06-07 Chinese
金陵药业股份有限公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing amendments to the articles of association (章程) of Jinling Pharmaceutical Co., Ltd. It includes changes to governance structures, shareholder meeting procedures, board responsibilities, and other corporate governance matters. The content focuses on internal company rules, board and shareholder meeting protocols, and governance practices rather than financial results, audit opinions, or capital changes. There is no indication of financial statements, earnings data, or regulatory filings related to financial performance. The document is not a report publication announcement or a certification. Therefore, the document best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-06-07 Chinese
金陵药业股份有限公司章程（2022.06）
Governance Information Classification · 95% confidence The document is the Articles of Association (章程) of Jinling Pharmaceutical Company Limited, detailing the company's organizational structure, shareholder rights, board and management roles, share issuance and transfer rules, shareholder meeting procedures, and other governance matters. It is a comprehensive governance document that outlines the internal rules and regulations of the company rather than a financial report, announcement, or other filing types. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is the full governance document, not a brief announcement or summary. Therefore, the correct classification is CGR with high confidence.
2022-06-07 Chinese
金陵药业股份有限公司关于召开2021年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders. The document does not contain the actual annual report or financial statements but rather the announcement and details related to the AGM itself. The length is over 6,000 characters, indicating a full notice rather than a brief announcement. Therefore, this document fits the category of AGM Information (AGM-R).
2022-06-07 Chinese
金陵药业股份有限公司董事会议事规则修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing amendments to the company's Board of Directors Meeting Rules (董事会议事规则修订对照表). It outlines changes in the powers and responsibilities of the board, including investment decisions, appointment and dismissal of senior management, financial approvals, and other governance matters. There is no indication of financial statements, audit opinions, earnings data, or shareholder voting results. The content focuses on governance structure and board procedures, which aligns with governance information rather than financial reporting or announcements. Therefore, the document best fits the category of Governance Information (CGR). The document length (13,452 characters) supports that this is a substantive document, not a brief announcement or certification.
2022-06-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.